The Most Important Facts About Agenus (AGEN)

One of the losers of Friday's trading session was Agenus. Shares of the Biotechnology company plunged -9.09%, and some investors may be wondering if its price of $1.5 would make a good entry point. Here's what you should know if you are considering this investment:

  • Agenus has moved -46.62% over the last year, and the S&P 500 logged a change of -7.46%

  • AGEN has an average analyst rating of buy and is -78.04% away from its mean target price of $6.83 per share

  • Its trailing earnings per share (EPS) is $-0.82

  • Agenus has a trailing 12 month Price to Earnings (P/E) ratio of -1.83 while the S&P 500 average is 15.97

  • Its forward earnings per share (EPS) is $-0.74 and its forward P/E ratio is -2.03

  • The company has a Price to Book (P/B) ratio of 218.61 in contrast to the S&P 500's average ratio of 2.95

  • Agenus is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16

  • Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.